Trial Profile
A Phase 1/2a Randomized, Double-Blind, Two-Part, Dose-Ascending, Multicenter Study of the Safety and PK of AR-501 (Gallium Citrate), Administered Via Inhalation, in Healthy Adult and P. Aeruginosa Infected Cystic Fibrosis Subjects
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2023
Price :
$35
*
At a glance
- Drugs Gallium citrate (Primary)
- Indications Cystic fibrosis; Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
- Focus Adverse reactions
- Sponsors Aridis Pharmaceuticals
- 03 Nov 2023 According to an Aridis Pharmaceuticals media release , Primary endpoint (Respiratory tolerability - Multiple Ascending Dose description: Spirometry) has been met.
- 03 Nov 2023 According to an Aridis Pharmaceuticals media release ,Primary endpoint (Clinical safety profile (adverse events) - Single Ascending Dose) has been met.
- 03 Nov 2023 Results presented in Aridis Pharmaceuticals media release.